Home »  In the Press » PRESS RELEASES 2007 » 2006 » 2005 »  2004 »  2003 Tranzyme Pharma Receives Notices of Allowance from USPTO on Two Patents Protecting Company’s Lead Pharmaceutical Development Programs » July 22, 2008 Tranzyme Pharma Announces Successful Thorough QT/QTc Study of Ghrelin Agonist TZP-101 » June 23, 2008 Tranzyme Pharma’s Ghrelin Agonist TZP-102 Demonstrates Safety and High Oral Bioavailability in the Successful Completion of a Phase I Trial » June 17, 2008 Tranzyme Pharma to Present “Ghrelin Agonist (TZP-101) Effects on Patients with Severe Symptomatic Diabetic Gastroparesis” at ADA 2008 » June 05, 2008 Tranzyme Pharma Receives IND Clearance for Its Oral Ghrelin Agonist, TZP-102, for the Treatment of Gastroparesis » January 29, 2008 Tranzyme Pharma to Present at the 26th Annual JPMorgan Healthcare Conference » December 19, 2007 Tranzyme Pharma Closes New $20 Million Financing » November 1, 2007 Tranzyme Pharma Initiates Dosing of Patients in a Multi-National Phase IIb Clinical Trial for the Treatment of Severe Gastroparesis » October 30, 2007 Tranzyme Pharma’s Motilin Antagonist TZP-201 Shows Potential for Preventing and Treating Chemotherapy-Induced Diarrhea (CID) » October 24, 2007 Tranzyme Pharma Initiates Dosing of Patients in a Multi-National Phase IIb Clinical Trial with its Novel Ghrelin Agonist, TZP-101, for Post-Operative Ileus » July 26, 2007 Tranzyme Pharma Receives FDA Fast Track Designation for its Novel Ghrelin Agonist, TZP-101, for the Treatment of Severe Gastroparesis » July 12, 2007 Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis » June 26, 2007